Literature DB >> 25929957

French multicentric validation of ALK rearrangement diagnostic in 547 lung adenocarcinomas.

Sylvie Lantuejoul1, Isabelle Rouquette2, Hélène Blons3, Nolwenn Le Stang4, Marius Ilie5, Hugues Begueret6, Valerie Grégoire7, Paul Hofman5, Audrey Gros6, Stephane Garcia8, Nathalie Monhoven9, Mojgan Devouassoux-Shisheboran10, Audrey Mansuet-Lupo11, Françoise Thivolet12, Martine Antoine13, Jean-Michel Vignaud9, Frederique Penault-Llorca14, Françoise Galateau-Sallé4, Anne McLeer-Florin15.   

Abstract

Anaplastic lymphoma kinase (ALK) gene rearrangements in lung adenocarcinoma result in kinase activity targetable by crizotinib. Although fluorescence in situ hybridisation (FISH) is the reference diagnostic technique, immunohistochemistry (IHC) could be useful for pre-screening. Diagnostic yields of ALK IHC, FISH and quantitative reverse transcriptase PCR performed in 14 French pathology/molecular genetics platforms were compared. 547 lung adenocarcinoma specimens were analysed using 5A4 and D5F3 antibodies, two break-apart FISH probes and TaqMan kits. Clinicopathological data were recorded. 140 tumours were ALK rearranged (FISH with ≥15% of rearranged cells) and 400 were ALK FISH negative (<15%). FISH was not interpretable for seven cases. ALK patients were young (p=0.003), mostly females (p=0.007) and light/nonsmokers (p<0.0001). 13 cases were IHC negative but FISH ≥15%, including six cases with FISH between 15% and 20%; eight were IHC positive with FISH between 10% and 14%. Sensitivity and specificity for 5A4 and D5F3 were 87% and 92%, and 89% and 76%, respectively. False-negative IHC, observed in 2.4% of cases, dropped to 1.3% for FISH >20%. Variants were undetected in 36% of ALK tumours. Discordances predominated with FISH ranging from 10% to 20% of rearranged cells and were centre dependent. IHC remains a reliable pre-screening method for ALK rearrangement detection.
Copyright ©ERS 2015.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25929957     DOI: 10.1183/09031936.00119914

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  19 in total

1.  Author's Reply to Arnaud Uguen: "Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02-14 Study)".

Authors:  Jean-Bernard Auliac; Christos Chouaid
Journal:  Target Oncol       Date:  2017-12       Impact factor: 4.493

2.  Comment on: "Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02-14 Study)".

Authors:  Arnaud Uguen
Journal:  Target Oncol       Date:  2017-12       Impact factor: 4.493

Review 3.  Anaplastic Lymphoma Kinase Testing: IHC vs. FISH vs. NGS.

Authors:  Xiaomin Niu; Jody C Chuang; Gerald J Berry; Heather A Wakelee
Journal:  Curr Treat Options Oncol       Date:  2017-11-16

4.  Ligation-dependent RT-PCR: a new specific and low-cost technique to detect ALK, ROS, and RET rearrangements in lung adenocarcinoma.

Authors:  Nicolas Piton; Philippe Ruminy; Claire Gravet; Vinciane Marchand; Élodie Colasse; Aude Lamy; Cécile Le Naoures Mear; Fréderic Bibeau; Florent Marguet; Florian Guisier; Mathieu Salaün; Luc Thiberville; Fabrice Jardin; Jean-Christophe Sabourin
Journal:  Lab Invest       Date:  2017-12-18       Impact factor: 5.662

5.  An improved assay for detection of theranostic gene translocations and MET exon 14 skipping in thoracic oncology.

Authors:  Nicolas Piton; Marie-Delphine Lanic; Florent Marguet; Aude Lamy; France Blanchard; Florian Guisier; Mathieu Viennot; Mathieu Salaün; Luc Thiberville; Fabrice Jardin; Jean-Christophe Sabourin; Philippe Ruminy
Journal:  Lab Invest       Date:  2021-01-25       Impact factor: 5.662

Review 6.  Immunohistochemistry for predictive biomarkers in non-small cell lung cancer.

Authors:  Mari Mino-Kenudson
Journal:  Transl Lung Cancer Res       Date:  2017-10

7.  Custom Gene Capture and Next-Generation Sequencing to Resolve Discordant ALK Status by FISH and IHC in Lung Adenocarcinoma.

Authors:  Jin Sung Jang; Xiaoke Wang; Peter T Vedell; Ji Wen; Jinghui Zhang; David W Ellison; Jared M Evans; Sarah H Johnson; Ping Yang; William R Sukov; Andre M Oliveira; George Vasmatzis; Zhifu Sun; Jin Jen; Eunhee S Yi
Journal:  J Thorac Oncol       Date:  2016-06-22       Impact factor: 15.609

8.  Screening for ALK Rearrangements in Lung Cancer: Time for a New Generation of Diagnostics?

Authors:  Ibiayi Dagogo-Jack; Alice T Shaw
Journal:  Oncologist       Date:  2016-05-31

9.  The prognostic value of serum CA 19-9 for patients with advanced lung adenocarcinoma.

Authors:  Yuki Sato; Daichi Fujimoto; Keiichiro Uehara; Ryoko Shimizu; Jiro Ito; Mariko Kogo; Shunsuke Teraoka; Ryoji Kato; Kazuma Nagata; Atsushi Nakagawa; Kojiro Otsuka; Hiroshi Hamakawa; Yutaka Takahashi; Yukihiro Imai; Keisuke Tomii
Journal:  BMC Cancer       Date:  2016-11-14       Impact factor: 4.430

10.  ALK-rearranged pulmonary adenocarcinoma in Thai Patients: From diagnosis to treatment efficacy.

Authors:  Pimpin Incharoen; Thanyanan Reungwetwattana; Sakditad Saowapa; Kaettipong Kamprerasart; Duangjai Pangpunyakulchai; Lalida Arsa; Artit Jinawath
Journal:  World J Surg Oncol       Date:  2016-05-03       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.